ATLAS fair value
$13.75
Below fair value · 21% discount
Puma Biotechnology stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
Prices as of Oct 27, 2026 · USD
$13.75
Below fair value · 21% discount
48%
that it ends higher than today in 21 sessions
ATLAS's own quantitative analysis, all in one place.
Plans from €3.99 a month.
ATLAS estimates Puma Biotechnology's fair value at about $13.75 per share (reasonable range: $10.42 to $15.63). At $10.92, the stock trades 21% below it.
It is calculated with a blend of a discounted cash-flow model and peer valuation multiples. Confidence in the estimate is medium. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives Puma Biotechnology a 48% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $9.91 and $11.90; in 9 out of 10, between $8.42 and $13.99. Estimated annual volatility is 46%.
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. Puma Biotechnology sits below fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks PBYI has traded between $4.58 and $11.50. Today it is 5.0% below that high and 138% above its low.
On the business: revenue fell 0.9% year over year; net margin is 13.6%; it trades at 18.4 times earnings.
Its beta is 1.23: it tends to move more than the market, both up and down.
Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing therapies that support cancer care.
Want to see everything about Puma Biotechnology?
Get started →Plans from €3.99 a month.
Other companies in the same line of business:
About $13.75 per share according to ATLAS (reasonable range: $10.42 to $15.63). With the stock at $10.92, it is 21% below it.
48%: close to a coin flip. In half of the simulated outcomes, PBYI ends the month between $9.91 and $11.90.
Puma Biotechnology's market capitalization is $491M. Its price-to-earnings (P/E) ratio is 18.4: you pay $18.4 for each $1 of yearly earnings.
ATLAS estimates annual volatility at 46%. In a typical month, half of the outcomes end between $9.91 and $11.90.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer
ATLAS Signals
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy